Ophthalmology Times

08/31/2025

From June 13-14, 2025, Heidelberg Engineering welcomed clinicians to its eponymous hometown of Heidelberg, Germany, and its brand-new campus for the 21st International SPECTRALIS Symposium (ISS)—and Beyond. The 2-day conference was hosted in the newly opened Heidelberg Congress Center and included tours of the company’s SkyLabs tower. The congress made good use of the setting, with a scenic cruise down the Neckar River on 2 riverboats.

Congress organizers also made the most of the elite corps of clinicians and researchers on the scientific faculty. Presenters shared 35 lectures across 7 topics, all helmed by course director Frank Holz, MD, FEBO, FARVO, professor and chair of the Department of Ophthalmology at the University of Bonn in Germany.

Read More:

Recapping the Heidelberg Engineering International SPECTRALIS Symposium—and Beyond.

08/30/2025

Zhehuan Zhang, MD, and colleagues from the Department of Ophthalmology, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, emphasized the importance of patients undergoing routine optical coherence tomography (OCT) scans during repeated low-level red-light (RLRL) therapy in order to detect retinal changes.

In this study, they noticed axial elongation and spherical equivalent refraction (SER) effects on myopia; however, in those treated with red light, they also found transient foveal RPE hyperreflectivity

Read More:

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

08/30/2025

A study published in Ophthalmology Science shows that by analyzing up-to daily home OCT images, artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD). This may allow physicians to manage patients by following biomarker trajectories over time and assessing treatment response.

The study evaluated data from 180 wet AMD patients and compared the AI-based Notal OCT Analyzer (NOA) generated outputs to annotations made by 3 expert graders. The results showed high agreement between NOA and human experts in identifying clinically meaningful changes.

Read More:

AI enhances home OCT imaging to track wet AMD disease activity, enabling personalized patient management and improved treatment response monitoring.

08/30/2025

“Modern devices for delivering viscoelastics during viscocanaloplasty have changed greatly over the past few years, resulting in better outcomes with improved ergonomics and user-friendliness for the surgeons who are performing the procedures,” said Edward Yung, MD, of the Pacific Eye Institute in Rancho Cucamonga, California.

Yung moderated a recent Ophthalmology Times Case-Based Roundtable on advancing surgical techniques with innovative viscoelastic delivery in glaucoma cases.

Read More:

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

08/29/2025

See you in sunny Florida! From September 26–27, EyeCon 2025 will be at the Margaritaville Hollywood Beach Resort. Join Vishakha Thakrar, OD, FAAO, FSLS, and other leaders in eye care!

Engage with top educators, hear the latest advances in eye care, and network with your peers. Hear from our exceptional education committee: Tosin U. Smith, MD; Jade Coats, OD; Sruthi Arepalli, MD; and Joseph Allen, OD, FAAO, Dipl ABO.

Sign up NOW for EyeCon 2025! Click here: https://hubs.li/Q03xH3hJ0

Earn up to 14 CME/COPE credits as you enjoy the beautiful weather at Hollywood Beach. Don’t miss the chance to connect and grow with the eye care community! Use code THAKRAR for 50% off of your registration!

08/29/2025

Dry eye disease (DED), as defined by the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II), is a multifactorial disease of the ocular surface. The etiological roles of DED are tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities. The burden of DED in ophthalmology is highlighted by community-based estimates indicating epidemic proportions in countries with large aging populations.

Although a wide array of therapeutic options exist for managing DED, the most severe forms—particularly those arising from conjunctival cicatricial disorders such as Stevens-Johnson syndrome (SJS) and ocular cicatricial mucous membrane pemphigoid—often pose a challenge because of the near-total or total loss of tear production. Noninvasive treatments are often insufficient in these cases, leaving patients vulnerable to severe complications that can result in blindness. This unmet need has driven the exploration of alternative interventions.

Read More:

A novel use of minor salivary glands offers lasting relief and visual improvement.

08/28/2025

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD).

The recent CRL included only 1 deficiency, for a lack of substantial evidence of effectiveness. According to Outlook, the FDA advised in the CRL that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. The pre-specified non-inferiority endpoint at week 8 was set forth in the special protocol assessment (SPA) with the FDA at the end of 2023.

Read More:

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

08/28/2025

Modern ophthalmology has some exciting tools to offer. However, as authors Esteban Peralta Chacon, MD, and William F. Wiley, MD, have learned, helping patients with a history of LASIK regain spectacle independence is equal parts exciting and challenging

Read More:

Innovation, adaptability, and clear communication are key to managing outcomes.

08/27/2025

The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG). The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s lead investigational therapy, will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with NTG and will be conducted at multiple clinical sites across South Korea, according to a news release.

Read More:

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

08/27/2025

Cataract surgery in patients who have previously undergone refractive procedures, such as LASIK or radial keratotomy (RK), presents unique challenges, noted Steven J. Dell, MD, medical director of Dell Laser Consultants in Austin, Texas, during an Ophthalmology Times Case-Based Roundtable. These challenges include precise IOL power calculation, variable epithelial healing, and specialized solutions such as piggyback lenses and customized lens selection to meet high expectations for spectacle independence.

Read More:

Surgeons navigate unpredictable healing and anatomy with customized strategies.

08/26/2025

See you in sunny Florida! From September 26–27, EyeCon 2025 will be at the Margaritaville Hollywood Beach Resort. Join Prem Subramanian, MD, PhD, Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology at University of Colorado School of Medicine, Department of Ophthalmology, and other leaders in eye care!

Engage with top educators, hear the latest advances in eye care, and network with your peers. Hear from our exceptional education committee: Tosin U. Smith, MD; Jade Coats, OD; Sruthi Arepalli, MD; and Joseph Allen, OD, FAAO, Dipl ABO.

Sign up NOW for EyeCon 2025! Click here: https://hubs.li/Q03xyVrZ0

Earn up to 14 CME/COPE credits as you enjoy the beautiful weather at Hollywood Beach. Don’t miss the chance to connect and grow with the eye care community! Use code SUBRAMANIAN for 50% off of your registration!

08/26/2025

Kriya Therapeutics reported in an SEC filing it has raised $313.3 million in a recent funding round.

The filing does not detail fund specificity or funding sources but rather only states two investors participated in the funding push. This $313.3 million adds to the company’s $100 million Series B raise in July 2021 and $270 million Series C round in May 2022, which was then extended by $150 million in July 2023.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.